Skip to main content

Table 4 Univariate and multivariate analysis of independent predictors for treatment success

From: Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China

Independent factors Treatment success Univariate analysis Multivariate analysis
  OR (95%CI) p value OR (95%CI) p value
Age      
 < 35 years 72 (85.7)
 35–60 years 73 (73.0) 0.45 (0.2–1.0) 0.04 2.7 (0.6–11.4) 0.2
 ≥ 60 years 14 (77.8) 0.6 (0.16–2.1) 0.6 1.0 (0.3–3.6) 1.0
Type of drug resistance    
 RR 5 (62.5)
 MDR 116 (76.3) 0.83 (0.2–3.8) 0.8
 XDR 36 (58.1) 2.7 (0.6–11.9) 0.2
Gender (male/female) 114 (77.0)/42 (79.2) 0.9 (0.4–1.9) 0.8
History of TB treatment (new/previously treated) 16 (84.2)/141 (77.0) 1.6 (0.4–5.7) 0.5
Cavitary disease at baseline (yes/no) 114 (81.4)/39 (72.2) 0.6 (0.3–1.2) 0.2
Concomitant diabetes (yes/no) 21 (72.4)/136 (78.6) 1.4 (0.6–3.4) 0.5
Treatment regimen (bedaquiline/non-bedaquiline) 94 (92.2)/63 (63.0) 6.9 (3.0–15.8) < 0.001* 7.4 (2.9–18.5) < 0.001*
Regimen containing (BDQ+ Cfz)/Cfz 87 (94.6)/29(58.0) 12.6 (4.4– 36.4) <0.001* 13.0 (4.4 –38.1) < 0.001*
Regimen containing (BDQ+ Lzd)/Lzd 85 (92.4)/13 (56.5) 9.3(3.0 –28.9) <0.001* 13.7 (1.8–103.8) 0.01*
Regimen containing (BDQ+ FQs)/FQs 19 (82.6)/45(57.7) 3.5 (1.1–11.2 ) 0.03* 2.5 (0.5–12.6 ) 0.27
Regimen containing (BDQ+Cs)/Cs 71(92.2)/58 (63.7) 6.7 (2.6–17.2) < 0.001* 13.1 (3.7–45.7) < 0.001*
BDQ+injectable agents/injectable agents 52 (96.3/60) (65.9) 13.4 (3.1–58.9) < 0.001* 12.1 (2.7–53.7) 0.001*
BDQ + Lzd+ FQs/Lzd+FQs 14 (82.4)/9 (50.0) 4.7 (0.1–22.0) 0.08 15.2 (1.42–163.3) 0.03*
BDQ+ Lzd+ FQs+ Cfz/Cfz+ Lzd+ FQs 15 (88.2)/3 (33.3) 15.0 (2.0–113.6) 0.01* 38.9 (1.9–817.1) 0.02*
  1. TB tuberculosis, RR rifampicin-resistant, MDR multidrug-resistant, XDR extensively drug-resistant, 95%CI 95% confidence interval, OR odds ratio
  2. * the differences had statistical significance (p < 0.05)